Core Viewpoint - The company is expanding its pharmaceutical business by diversifying into emerging sectors while consolidating its established small molecule CDMO services [1] Group 1: Business Expansion - The company is focusing on expanding its service areas in the pharmaceutical sector [1] - It is investing heavily in new business areas such as peptide products, radiopharmaceutical-related CDMO, animal health CDMO, generic drug intermediates and APIs, and cosmetic raw materials [1] Group 2: Technical Capabilities - The company's technical capabilities have evolved from traditional small molecules to include amino acids, peptides, PROTAC/ADC linkers, and oligonucleotides [1] - It has experience in delivering from linker grams to hundreds of grams, enabling the design and optimization of synthetic routes for clients [1] - This capability supports the transition of early clinical projects [1]